Skip to content

Research at St Andrews

Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials

Research output: Contribution to journalArticle

DOI

Open Access permissions

Open

Author(s)

Patrick P. J. Phillips, Carl M. Mendel, Divan A. Burger, Angela Crook, Andrew J. Nunn, Rodney Dawson, Andreas H. Diacon, Stephen Henry Gillespie

School/Research organisations

Abstract

Background
Despite recent increased clinical trials activity, no regimen has proved able to replace the standard 6-month regimen for drug-sensitive tuberculosis. Understanding the relationship between microbiological markers measured during treatment and long-term clinical outcomes is critical to evaluate their usefulness for decision-making for both individual patient care and for advancing novel regimens into time-consuming and expensive pivotal phase III trials.

Methods
Using data from the randomized controlled phase III trial REMoxTB, we evaluated sputum-based markers of speed of clearance of bacilli: time to smear negative status; time to culture negative status on LJ or in MGIT; daily rate of change of log10(TTP) to day 56; and smear or culture results at weeks 6, 8 or 12; as individual- and trial-level surrogate endpoints for long-term clinical outcome.

Results
Time to culture negative status on LJ or in MGIT, time to smear negative status and daily rate of change in log10(TTP) were each independent predictors of clinical outcome, adjusted for treatment (p <0.001). However, discrimination between low and high risk patients, as measured by the c-statistic, was modest and not much higher than the reference model adjusted for BMI, history of smoking, HIV status, cavitation, gender and MGIT TTP.

Conclusions
Culture conversion during treatment for tuberculosis, however measured, has only a limited role in decision-making for advancing regimens into phase III trials or in predicting the outcome of treatment for individual patients. REMoxTB ClinicalTrials.gov number: NCT00864383.
Close

Details

Original languageEnglish
Article number19
Pages (from-to)1-11
Number of pages11
JournalBMC Medicine
Volume14
DOIs
StatePublished - 4 Feb 2016

    Research areas

  • Tuberculosis, Clinical trials, Surrogate endpoints, Moxifloxacin

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Pseudomonas aeruginosa intensive care unit outbreak: winnowing of transmissions with molecular and genomic typing

    Parcell, B. J., Oravcova, K., Pinheiro, M., Holden, M. T. G., Phillips, G., Turton, J. F. & Gillespie, S. H. 8 Dec 2017 In : Journal of Hospital Infection. In press

    Research output: Contribution to journalArticle

  2. Project Sanitarium: playing tuberculosis to its end game

    Donald, I., Meyer, K., Brengman, J., Gillespie, S. H. & Bowness, R. Dec 2017 In : Journal of Computing in Higher Education. 29, 3, p. 599-617 19 p.

    Research output: Contribution to journalArticle

  3. A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens

    Phillips, P. P. J., Mendel, C. M., Nunn, A. J., McHugh, T. D., Crook, A. M., Hunt, R., Bateson, A. & Gillespie, S. H. 24 Nov 2017 In : BMC Medicine. 15, 9 p., 207

    Research output: Contribution to journalArticle

  4. Pharmacokinetics, tolerability, and bacteriological response of rifampin administered at 600, 900, and 1,200 milligrams daily in patients with pulmonary tuberculosis

    Aarnoutse, R. E., Kibiki, G. S., Reither, K., Semvua, H. H., Haraka, F., Mtabho, C. M., Mpagama, S. G., van den Boogaard, J., Sumari-de Boer, I. M., Magis-Escurra, C., Wattenberg, M., Logger, J. G. M., te Brake, L. H. M., Hoelscher, M., Gillespie, S. H., Colbers, A., Phillips, P. P. J., Plemper van Balen, G., Boeree, M. J. & PanACEA Consortium 1 Nov 2017 In : Antimicrobial Agents and Chemotherapy. 61, 11, e01054-17

    Research output: Contribution to journalArticle

  5. Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis

    Murphy, M. E., Phillips, P. P. J., Mendel, C. M., Bongard, E., Bateson, A. L. C., Hunt, R., Murthy, S., Singh, K. P., Brown, M., Crook, A. M., Nunn, A. J., Meredith, S. K., Lipman, M., McHugh, T. D., Gillespie, S. H. & on behalf of the REMoxTB Consortium 27 Oct 2017 In : BMC Medicine. 15, 10 p., 192

    Research output: Contribution to journalArticle

Related by journal

  1. A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens

    Phillips, P. P. J., Mendel, C. M., Nunn, A. J., McHugh, T. D., Crook, A. M., Hunt, R., Bateson, A. & Gillespie, S. H. 24 Nov 2017 In : BMC Medicine. 15, 9 p., 207

    Research output: Contribution to journalArticle

  2. Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis

    Murphy, M. E., Phillips, P. P. J., Mendel, C. M., Bongard, E., Bateson, A. L. C., Hunt, R., Murthy, S., Singh, K. P., Brown, M., Crook, A. M., Nunn, A. J., Meredith, S. K., Lipman, M., McHugh, T. D., Gillespie, S. H. & on behalf of the REMoxTB Consortium 27 Oct 2017 In : BMC Medicine. 15, 10 p., 192

    Research output: Contribution to journalArticle

  3. Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer

    Lubbock, A. L. R., Stewart, G. D., O'Mahoney, F. C., Laird, A., Mullen, P., O'Donnell, M., Powles, T., Harrison, D. J. & Overton, I. M. 26 Jun 2017 In : BMC Medicine. 15, 12 p., 118

    Research output: Contribution to journalArticle

  4. Profiling persistent tubercule bacilli from patient sputa during therapy predicts early drug efficacy

    Honeyborne, I., McHugh, T. D., Kuittinen, I., Cichonska, A., Evangelopoulos, D., Ronacher, K., van Helden, P. D., Gillespie, S. H., Fernandez-Reyes, D., Walzl, G., Rousu, J., Butcher, P. D. & Waddell, S. J. 7 Apr 2016 In : BMC Medicine. 14, 1, p. 1-13 13 p.

    Research output: Contribution to journalArticle

  5. A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)

    Phillips, P. P. J., Dooley, K. E., Gillespie, S. H., Heinrich, N., Stout, J. E., Nahid, P., Diacon, A. H., Aarnoutse, R. E., Kibiki, G. S., Boeree, M. J. & Hoelscher, M. 23 Mar 2016 In : BMC Medicine. 14, p. 1-11 11 p., 51

    Research output: Contribution to journalArticle

ID: 240893266